Eli Lilly (LLY)
(Delayed Data from NYSE)
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
Zacks News
Lilly (LLY) Stock Up on Raised 2021 View, Upbeat 2022 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock rallies after it raises 2021 profit and sales outlook and provides an upbeat financial guidance for the next year.
Lilly (LLY) Stock Jumps 10.4%: Will It Continue to Soar?
by Zacks Equity Research
Lilly (LLY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Biotech Stock Roundup: BMY Increases Dividend, MRNA's Study Results & More
by Zacks Equity Research
Moderna's (MRNA) vaccine study results and other pipeline updates have been the biotech sector???s few key highlights during the past week.
Lilly (LLY) Phase III Study in Ulcerative Colitis Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) mirikizumab meets primary and key secondary endpoints in a phase III maintenance study in ulcerative colitis.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Foghorn (FHTX) Surges on Oncology Collaboration With Lilly
by Zacks Equity Research
Foghorn (FHTX) soars following a collaboration with pharma giant Lilly for novel oncology targets.
Company News for Dec 14, 2021
by Zacks Equity Research
Companies In The News Are: ARNA, PFE, LLY, FHTX, TPX, NAVI.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $248.53, moving +1.8% from the previous trading session.
Lilly (LLY) Inks Metabolic Disorders Therapy Development Deal
by Zacks Equity Research
Lilly (LLY) inks a strategic collaboration with Regor Therapeutics to discover and develop novel therapies for metabolic disorders.
Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod
by Kinjel Shah
Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.
AstraZeneca (AZN) Gets FDA Nod for COVID Prevention Drug
by Zacks Equity Research
With emergency approval from the FDA, AstraZeneca's (AZN) Evusheld is the first cocktail antibody drug approved in the United States to prevent COVID-19 symptoms before virus exposure.
Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study
by Zacks Equity Research
Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.
Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19
by Zacks Equity Research
The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.
AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label
by Zacks Equity Research
AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.
Lilly (LLY) COVID-19 Antibody Gets FDA Nod for Use in Kids
by Zacks Equity Research
With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.
Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote
by Zacks Equity Research
An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.
Top Research Reports for Mastercard, Pfizer & Nike
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Pfizer Inc. (PFE), and NIKE, Inc. (NKE).
Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down
by Zacks Equity Research
Merck's (MRK) new data from a phase III study shows its COVID-19 antiviral pill is less effective than previously reported.
Lilly (LLY) Up 4.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote
by Zacks Equity Research
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government
by Zacks Equity Research
Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk
Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.
3 Big Pharma Outperformers to Watch Out For in the Near Term
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP